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Abstract
Anemia in chronic kidney disease is common and iron deﬁciency is an important cause. To repair
iron-deﬁciency anemia, replacement of iron is needed. Iron can be replaced either by the oral route
or by the intravenous route. In a meta-analysis, 5 of the 6 trials were short-term, 1 to 3 months,
and compared to oral iron, the mean increase in hemoglobin with intravenous iron was only
0.31 g/dL. However, one of the studies included in this meta-analysis was 6 months long and had
a mean decline in hemoglobin of 0.52 g/dL associated with intravenous iron administration. Given
the short duration of most of the clinical trials comparing oral with intravenous administration of
iron the long-term safety of these modes of administration of supplemental iron could not be
assessed. Replacement of iron by the oral route is associated with mostly minor complications
such as black stools, constipation, and abdominal discomfort. In contrast, intravenous administra-
tion of iron may lead to severe adverse events such as anaphylaxis and, as a more recent random-
ized trial has suggested, delayed complications such as infections and cardiovascular disease.
Delayed complications of repeated intravenous iron use are difﬁcult to recognize at an individual
level therefore inpatients who have had recent cardiovascular events or are infected, intravenous
iron should probably be avoided. Balancing safety and efﬁcacy would require clinical judgment
because 1 size may not ﬁt all till we have better data to support the liberal use of parenteral iron.
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INTRODUCTION
Anemia in chronic kidney disease (CKD) is common. It
occurs when serum creatinine becomes abnormal1; this
usually occurs when estimated glomerular filtration rate
(eGFR) drops to 60 mL/min/1.73 m2 or less. The preva-
lence of anemia increases with worsening kidney
function. For any given severity of eGFR, anemia is worse
in those with diabetes mellitus.2 Anemia is more prevalent
in women than in men.1 The etiology of anemia in CKD
is multifactorial.3 Relative erythropoietin deficiency is
common, but also other factors that make the marrow
less responsive to erythropoietin are prevalent. Inflamma-
tion and iron deficiency are most common among these
factors.3
The diagnosis of iron-deficiency anemia in CKD is diffi-
cult. The most common biomarkers used to gauge the
sufficiency of iron storage are ferritin concentration and
transferrin saturation. Both ferritin concentration and
transferrin saturation decline in iron-deficiency anemia.
The thresholds of ferritin and transferrin at which iron
stores are deficient are not known. Although opinions
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exist on what these thresholds should be, the scientific
evidence to back these thresholds is soft.3 Ferritin, for
example, is a positive acute-phase reactant. In other
words, its concentrations increase in the setting of inflam-
mation. Transferrin, conversely, is a negative acute-phase
reactant; its concentrations decrease in patients with
inflammation. Accordingly, in an iron-deficient patient,
the ferritin concentration may be high and transferrin sat-
uration may be low even in the setting of inflammation.
MANAGEMENT OF IRON-DEFICIENCY
ANEMIA IN PATIENTS WITH CKD
To repair iron-deficiency anemia, replacement of iron is
needed. Iron can be replaced either by the oral route or by
the intravenous route; more recently, replacement through
the dialysate has become available, but it will not be the
subject of this discussion. Replacement of iron by the oral
route is associated with mostly minor complications such
as black stools, constipation, and abdominal discomfort. In
predisposed populations, even oral iron replacement can
be dangerous as discussed later. In contrast, intravenous
administration of iron may lead to severe adverse events
such as anaphylaxis.4 Anaphylaxis is rare, but it can occa-
sionally be fatal. Typically seen as a complication of large
molecular weight IV dextrans, it has also been reported
with small molecular weight iron dextran as well as feru-
moxytol.5 Less recognized are the long-term consequences
of intravenous iron replacement in patients with CKD.6
EFFICACY OF ORAL VS.
INTRAVENOUS IRON IN CKD
A meta-analysis of small randomized trials reported the
efficacy of oral compared with intravenous iron on hemo-
globin response in CKD patients not on dialysis.7 Five of
the 6 trials reported in this meta-analysis were short-term,
1 to 3 months, and compared to oral iron, the mean
increase in hemoglobin with intravenous iron was 0.31
(95% confidence interval (CI) 0.09 to 0.53) g/dL. Howev-
er, one of the studies included in this meta-analysis was 6
months long and had a mean decline in hemoglobin of
0.52 g/dL associated with intravenous iron administra-
tion.8 Given the short duration of most of the clinical tri-
als comparing oral with intravenous administration of
iron the long-term safety of these modes of administration
of supplemental iron could not be assessed.
Although the efficacy of intravenous iron is considered
self-evident, it must be recognized that such trials have
only lasted about 12 weeks. Steady state levels of
hemoglobin with oral iron may not be achieved with such
full therapies. In such patients with intravenous iron, it
does not prove that there is a better response, just a faster
response. Furthermore, the short duration of most of the
clinical trials comparing oral with intravenous administra-
tion of iron the long-term safety of these modes of admin-
istration of supplemental iron could not be assessed.
Accordingly, guidelines have no recommendation on the
preferred mode of iron administration in such patients.9
ASSESSMENT OF THE LONGER
TERM TRIALS OF IRON
REPLACEMENT IN CKD
Funded by the National Institutes of Health, the random-
ized trial to evaluate intravenous and oral iron in chronic
kidney disease (REVOKE) assigned 69 patients with Stage
3 and 4 CKD and IDA to either open-label oral ferrous
sulfate (325 mg 3 times daily for 8 weeks) and 67 patients
to intravenous (IV) iron sucrose (200 mg every 2 weeks,
total 1 gram). The primary outcome was the between
group difference in slope of measured glomerular filtration
rate (mGFR) change over 2 years. mGFR was measured
using after bolus dose of iothalamate. Clearance of iothala-
mate was calculated over 5 hours using 13 blood samples
on 5 occasions over 2 years. The number of samples pro-
vided a high mGFR precision. Despite these arduous
measurements in REVOKE, mGFR declined similarly over
2 years in both treatment groups (oral iron 23.6 mL/min/
1.73 m2, IV iron—4.0 mL/min/1.73 m2, between group
difference 20.35 mL/min/1.73 m2 (95% CI 22.9 to 2.3,
P5 0.79). However, the trial was terminated early on the
recommendation of an independent Data and Safety Moni-
toring Board based on little chance of finding differences
in mGFR slopes, but a higher risk of serious adverse
events in the IV iron treatment group. There were 36 seri-
ous cardiovascular events among 19 participants assigned
to the oral iron treatment group and 55 events among 17
participants of the IV iron group (adjusted incidence rate
ratio [IRR] 2.51 (95% CI 1.56–4.04, P< 0.001)]. Infec-
tions resulting in hospitalizations had an adjusted IRR of
2.12 (95% CI 1.24–3.64, P5 0.006). Notably, in
REVOKE, the incidences of all-cause hospitalizations, car-
diovascular adverse events, as well as infection-related
hospitalizations were all increased many fold in those
receiving intravenous iron. Furthermore, it was not the
number of patients but the number of events per patient
that was increased. In other words, intravenous iron can
increase the susceptibility of having more frequent
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cardiovascular and more frequent infection-related events
in those with CKD and iron deficiency anemia.
Funded by the manufacturer, in the Ferinject
VR
assess-
ment in patients with iron deficiency anemia and non-
dialysis-dependent chronic kidney disease (FIND-CKD)
investigators randomized 626 patients in 193 centers in
1:1:2 ratio to ferric carboxymaltose targeting ferritin to
high level (400–600 ng/mL), lower level (100–200 ng/
mL) or oral iron with the primary end-point of time to
initiation of other anemia management (erythropoetin
stimulating agents, other iron therapy or blood transfu-
sion) or hemoglobin trigger of 2 consecutive values
<10 g/dL during weeks 8 to 52.10 The investigators
reported the mean change in hemoglobin from baseline to
52 weeks as 1.0 g/dL in oral iron group, 0.9 g/dL when
IV ferric carboxymaltose targeted ferritin to 100 to 200
ng/mL and 1.4 g/dL (P5 0.26) when IV ferric carboxy-
maltose targeted ferritin to 400 to 600 ng/mL
(P5 0.014).10 Although statistically significant, the differ-
ence in hemoglobin of 0.4 g/dL between oral iron and
high dose IV iron observed in that study should be inter-
preted cautiously because the oral ferrous sulfate adminis-
tration was only 100 mg twice daily which is much below
the recommended intake of ferrous sulfate 325 mg 3
times daily. Of note, the REVOKE trial used this regimen
and found no between group differences in hemoglobin
response over a much longer follow up. Despite using
one third of the usual dose, there was no between group
differences seen when oral iron was compared to the low-
er ferritin target with intravenous iron. When iron use
was more aggressive in the higher ferritin target, the
hemoglobin target was only about 0.4 g/dL higher.
Iron and infections
The association with iron administration and infections is
biologically plausible. Iron promotes growth of even com-
mon bacteria such as Staphylococcus epidermidis.11 In addi-
tion, the inflammatory response to infection is
enhanced12,13 and phagocytic function of neutrophils has
been shown to be impaired by iron.14 In one study,
rodents given endotoxin when exposed to intravenous
iron were much more likely to die than rodents that did
not receive intravenous iron.
Risk of infection with oral iron is evident at least in some
studies in humans. In a large randomized year-long trial in
Tanzania, Africa, compared to placebo, the incidence of
fatal infections was increased when preschool children were
supplemented with oral iron and folic acid.15 With cumula-
tive follow-up of 25524 years, an increased risk of severe ill-
ness and death were noted with iron and the differences in
event rates did not emerge till after 90 days after being on
drug. Thus, the risk was not immediately apparent. Similar-
ly, in the REVOKE trial, the incidence of infections in those
receiving intravenous iron was increased.
Iron and cardiovascular events
The association between adverse cardiovascular events
and the administration of intravenous iron is poorly rec-
ognized but is biologically plausible.16–20 Compared with
oral iron, a greater iron saturation and a higher serum fer-
ritin concentration was seen in the IV iron group which
may increase the likelihood for the generation of free
iron. Free iron induces the generation of the hydroxyl ion
via the Haber-Weiss Fenton reaction, quenching of nitric
oxide, endothelial dysfunction and may accelerate athero-
sclerosis.21 In the iron deficient state, the endothelium
expresses the transferrin receptor, which can internalize
diferric transferrin within the endothelial cell. This can
lead to endothelial dysfunction and down-stream events.
Repeated administration of iron sucrose results in post
infusion proteinuria22; if this results in impaired sodium
handling by the kidney it may explain excess heart failure
hospitalizations. As an example, in the REVOKE trial, the
incidence of cardiovascular events and especially hospital-
ization for heart failure was elevated several fold.
UNCERTAINTIES AND CAUTIONS
Despite about year long duration of FIND-CKD and 2
years for REVOKE, the safety data are disparate and diffi-
cult to compare for several reasons.10 First, FIND-CKD
excluded patients whose CKD was progressing rapidly
and they could reach ESRD within 12 months. Second,
adverse events and serious adverse events are reported up
to the point at which another anemia therapy was initiat-
ed and/or the randomized study medication was discon-
tinued. In other words, if ESA was initiated or patient
transfused, the study stopped reporting serious adverse
events. The latter is a violation of the intention-to-treat
analysis. Third, serious adverse events were reported if
they occurred in at least 1% of the patients. Even so, the
investigators reported serious adverse events in 25.3%,
24.0%, and 18.9% of patients in the high-ferritin IV iron,
low-ferritin IV iron, and oral iron groups, respectively.
Thus, compared to oral iron group, IV iron SAE was
between 27% and 34% higher. Fourth, multiple events
within patients were not reported. In other words, multi-
ple CHF events in 1 patient would only be reported once.
REVOKE counted each event as a separate SAE. In fact,
the number of patients who had SAEs in REVOKE
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were similar between oral and IV iron groups. Indeed
REVOKE found that exposure to IV iron increased the
frequency—not the number of participants—with serious
adverse events.
Following the publication of REVOKE, the authors of
FIND-CKD reported a post hoc analysis of adverse event
rates per 100 patient-years to assess the safety of FCM
over oral iron.23 They criticize the REVOKE study for
using a nonstandard way of reporting adverse events
where repeated events per patient are reported instead
of just the first event. In their post hoc analyses the
FIND-CKD investigators did not find an elevated risk for
infections or cardiovascular events. But they note:
“Additionally, it should be borne in mind that safety
reporting was censored at the point at which another ane-
mia therapy (e.g., ESA or blood transfusion was initiated
and/or the patient discontinued the study drug). This
approach was taken in an attempt to obtain ‘clean’ data
sets, but this advantage is counterbalanced by the risk
that adverse events which first manifested after drug dis-
continuation would not be captured, and is thus a poten-
tial source of underreporting.” Besides, this is analysis is
violation of intention to treat—a standard of reporting in
clinical trials—and their report is what would be consid-
ered a per protocol analysis which is subject to bias.
Therefore, despite these post hoc reports the data gath-
ered during the conduct of FIND-CKD is inadequate to
prove safety.
In dialysis patients, intravenous iron is being used lib-
erally but there is no randomized trial to show safety of
this approach. Compared with patients studied in
REVOKE or FIND-CKD, dialysis patients are even at high
risk for cardiovascular events and infections. Cardiovascu-
lar complications and infection complications are difficult
to recognize outside a randomized trial setting. Oral iron
is apparently considered ineffective in this population,
but high quality trials are missing. Intravenous iron,
although considered standard of care, probably needs to
be compared with oral iron in such populations over a
longer duration to provide greater confidence that oral
iron truly is not effective. A new development has been
the use of dialysate iron. Whether such a strategy, which
exposes to less iron load, will result in fewer infections
and cardiovascular events remains to be seen.
For approval of drugs used to treat a high risk popula-
tions, the FDA requires establishing cardiovascular safety
of such drugs.15 For example, the FDA guidance states,
“if the premarketing application contains clinical data that
show that the upper bound of the 2-sided 95% CI for the
estimated increased risk (i.e., risk ratio) is between 1.3
and 1.8, and the overall risk-benefit analysis supports
approval, a postmarketing trial generally will be necessary
to definitively show that the upper bound of the 2-sided
95% CI for the estimated risk ratio is less than 1.3.”15 IV
iron is liberally used in patients with CKD, a population
that has a cardiovascular risk that is even higher than dia-
betes. Given that serious adverse events seen with IV iron
was between 27% and 34% higher even in the FIND-
CKD trial (and much higher in REVOKE), a trial to dem-
onstrate long-term safety is now needed.9
KDIGO guidelines on anemia management (2012) state
that “for CKD not-on-dialysis patients who require iron
supplementation, select the route of iron administration
based on the severity of iron deficiency, availability of
venous access, response to prior oral iron therapy, side
effects with prior oral or IV iron therapy, patient compli-
ance, and cost.”9 This statement is not graded. Since these
guidelines, several new trials suggest that a more cautious
approach would be to replete iron using the oral route as
first line therapy. Using elemental iron in a dose of at least
200 mg/day (equivalent to ferrous sulfate 325 mg orally 3
times daily) is recommended by the guidelines9 and would
be my first choice. If oral iron is not effective after a rigor-
ous attempt for 1 to 3 months, then compliance with ther-
apy should be evaluated and changes in frequency of the
agent may have to be addressed. If oral iron is deemed
ineffective, then intravenous iron in the lowest dose possi-
ble to replete iron may be administered. Delayed complica-
tions of repeated intravenous iron use are difficult to
recognize at an individual level therefore inpatients who
have had recent cardiovascular events or are infected,
intravenous iron should probably be avoided since it can
aggravate inflammation and promote adverse cardiovascu-
lar events. Balancing safety and efficacy would require clin-
ical judgement because 1 size may not fit all till we have
better data to support the liberal use of parenteral iron.
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